ReviewActa diabetologica2026
Association between data-driven diabetes subtypes and kidney, cardiovascular, and all-cause mortality outcomes in adults: a systematic review and meta-analysis.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsData-driven clustering has identified reproducible diabetes subtypes with distinct metabolic profiles and complication risks. However, their incremental prognostic value and clinical utility beyond conventional risk assessment remain uncertain. We conducted a systematic review and meta-analysis to evaluate associations between diabetes subtypes and long-term clinical outcomes in adults.
methodsPubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library were searched from inception through February 25, 2026, with an updated targeted literature search and citation/reference screening performed through August 2026. Observational cohort studies classifying adults with diabetes using data-driven clustering and reporting longitudinal kidney, cardiovascular, or mortality outcomes were included. Random-effects meta-analyses pooled study-reported hazard ratios (HRs), and narrative synthesis was conducted when pooling was not possible due to differences in comparator subtype, outcome definitions, or clustering frameworks.
resultsThirty-four eligible study reports were included; 12 contributed to quantitative synthesis and 22 were synthesized narratively. Because several reports drew on overlapping source cohorts, a unique review-wide participant total was not calculated. Compared with mild age-related diabetes (MARD), severe insulin-resistant diabetes (SIRD) demonstrated the strongest associations with kidney outcomes, including CKD stage ≥3 (HR 1.84; 95% CI 1.53-2.20), advanced CKD (HR 2.34; 95% CI 1.84-2.99), ESKD (HR 3.83; 95% CI 2.47-5.93), and incident macroalbuminuria (HR 2.08; 95% CI 1.39-3.12). Severe insulin-deficient diabetes (SIDD) was also associated with increased kidney risk. Cardiovascular associations were more heterogeneous, although SIDD was associated with increased cardiovascular mortality compared with mild obesity-related diabetes (MOD) (HR 1.89; 95% CI 1.37-2.62). In an exploratory two-study analysis using MOD as the reference subtype, both SIRD (HR 2.05; 95% CI 1.46-2.87) and SIDD (HR 2.04; 95% CI 1.25-3.32) were associated with increased all-cause mortality.
conclusionsData-driven diabetes subtypes are associated with differences in kidney, cardiovascular, and mortality risk, with the most consistent associations observed for SIRD and kidney outcomes. Whether subtype classification improves prediction or clinical decision-making beyond conventional risk factors remains uncertain. PROSPERO REGISTRATION NUMBER: CRD420261299731.
Indexed as
Identifiers
43012977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.